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resumo 
 
 
A terapia fotodinâmica (PDT) é uma modalidade promissora para o tratamento 
do cancro. Esta terapia baseia-se na interação entre um composto químico 
(fotossensibilizador, PS), luz com um determinado comprimento de onda e 
oxigénio molecular para originar a produção de espécies reativas de oxigénio 
(ROS).  Devido à sua elevada reatividade, estas espécies tóxicas podem 
causar danos severos conduzindo à morte celular. Atualmente, os PS 
disponíveis na clínica para o tratamento de tumores apresentam baixa 
seletividade para as células tumorais. Estudos anteriores do nosso grupo 
descreveram uma porfirina conjugada com unidades dendríticas de galactose 
(PorGal8) como um novo PS solúvel em solução aquosa, capaz de gerar ROS 
após fotoativação e com reconhecimento por parte de proteínas (galectina-1) 
que se encontram sobreexpressas nas células do cancro da bexiga. Vários 
estudos têm descrito alterações no citoesqueleto em resposta ao tratamento 
fotodinâmico. No entanto, a contribuição da desorganização do citoesqueleto 
na morte celular induzida por PDT encontra-se pouco esclarecida. 
Neste trabalho, avaliámos de que forma alterações nos constituintes do 
citoesqueleto – filamentos de actina, filamentos intermédios e microtúbulos – 
estão relacionadas com morte celular induzida por PDT com PorGal8. 
O uptake de PorGal8 em duas linhas celulares do cancro da bexiga derivadas 
de carcinoma de células transicionais (UM-UC-3 e HT-1376), foi dependente 
da concentração. O uptake celular de PorGal8 foi superior nas células UM-UC-
3, que exibem níveis superiores da proteína galectina-1, comparativamente 
com as células HT-1376. PorGal8 mostrou não ser tóxico no escuro. A 
fotoativação da PorGal8 resultou numa fototoxicidade significativamente 
superior nas células UM-UC-3 relativamente às células HT-1376. A PorGal8 
não induziu alterações significativas nos níveis de proteína α-tubulina nas 
células UM-UC-3. No entanto, observou-se uma redução significativa nos 
níveis de α-tubulina nas células HT-1376 vinte e quatro horas após tratamento 
com irradiação. Apesar de se ter observado uma recuperação na organização 
dos microtúbulos em algumas células, a intensidade da fluorescência diminuiu 
consideravelmente na maior parte das células HT-1376. Uma redução 
significativa nos níveis de proteína dos filamentos intermédios (vimentina) foi 
observada em ambas as linhas celulares vinte e quatro horas após irradiação. 
Trinta minutos após a irradiação, as células UM-UC-3 e HT-1376 
apresentaram uma clara retração nos filamentos de actina com perda de fibras 
de stress. Ao contrário das células UM-UC-3 em que não se verificaram sinais 
de recuperação, em algumas células HT-1376 verificou-se uma certa 
reorganização dos filamentos de actina, com curtas fibras de stress, longas 
extensões, grandes filopodia, o que parece sugerir uma possível recuperação 
das células HT-1376. A RhoA, uma proteína da família de pequenas proteínas 
GTPases, descrita como estando relacionada com a expressão da galectina-1, 
foi adicionalmente avaliada.  Resultados preliminares indicaram que a PorGal8 
induziu uma tendência para aumentar os níveis de RhoA nas células HT-1376 
vinte e quatro horas após tratamento com irradiação. 
Concluindo, os nossos resultados contribuem para o esclarecimento dos 
mecanismos subjacentes dos efeitos fototóxicos da PorGal8. Uma melhor 
compreensão dos intervenientes e das alterações induzidas imediatamente 
após PDT nas estruturas do citoesqueleto em cancros resistentes à terapia, 
poderão contribuir para o desenvolvimento de novos agentes terapêuticos 
adjuvantes à PDT. 
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abstract 
 
Photodynamic therapy (PDT) is a promising modality for the treatment of 
cancer that involves light of an appropriate wavelength and a photosensitizing 
drug (photosensitizer, PS), used in conjunction with molecular oxygen, leading 
to the production of reactive oxygen species (ROS). In a biological 
environment, these toxic species can interact with the cellular constituents 
eliciting cell death. Currently, the PS available show poor tumor specificity. 
Previous work from our research group reported a porphyrin conjugated with 
dendritic units of galactose (PorGal8) as a new water soluble PS, able to 
generate ROS after photoactivation and exhibiting increased selectivity to 
bladder cancer cells overexpressing galectin-1. Several studies reported 
cytoskeleton alterations derived from photodynamic treatments. However, the 
role of cytoskeleton disorganization in cell death induced by PDT remains 
unclear. 
In this work we evaluated whether changes in the cytoskeletal constituents - 
actin filaments, intermediate filaments and microtubules - are correlated with 
cell death triggered by PDT with PorGal8.  
The uptake of PorGal8 in two bladder cancer lines derived from transitional cell 
carcinoma (UM-UC-3 and HT-1376 cells), was concentration dependent. 
Cellular uptake of PorGal8 was higher in UM-UC-3 cells that express higher 
levels of galectin-1 protein than HT-1376 cells. PorGal8 was nontoxic in dark. 
Photoactivation of PorGal8 resulted in a significantly higher phototoxicity in UM-
UC-3 cells than HT-1376 cells. PorGal8 did not change the α-tubulin protein 
levels in UM-UC-3 cells but reduced α-tubulin twenty-four hours after 
photodynamic activation in HT-1376 cells. Although a few cells showed a 
recovery in microtubules organization, the fluorescence intensity decreased 
noticeably in most of the HT-1376 cells. A significant decrease in intermediate 
filaments (vimentin) protein levels was exhibited in both cell lines twenty-hours 
after irradiation. Thirty minutes post-irradiation, UM-UC-3 and HT-1376 cells 
showed a clear retraction of actin filaments with loss of stress fibers. Although 
no recovery was observed in UM-UC-3 cells, some cells present some 
reorganization in actin filaments, presenting short stress fibers, long 
extensions, like large filopodia, suggesting a possible recovery in HT-1376 
cells. A small GTPases family protein, RhoA, referred to be involved with 
galectin-1 expression, was also evaluated, with preliminary results indicating a 
tendency towards an increase in HT-1376 cells twenty-four hours after therapy. 
Overall, our results give new insights into the mechanisms underlying the 
phototoxic effects of PorGal8. Better understanding the intrinsic web of events 
and alterations on cytoskeleton structures induced immediately after 
photodynamic treatment in resistant cancers may contribute to envisage new 
potential therapeutic adjuvants for PDT.   
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Chapter 1. Introduction 
1.1 Bladder Cancer 
Bladder cancer has become a common malignancy worldwide, with an estimated 430,000 
new cases diagnosed in 2012 (Ferlay et al. 2013), and it is characterized by a high recurrence rate. 
Bladder cancer has higher prevalence in men than in women. The incidence and mortality 
rates per 100,000 in the European Union are 14.4 and 4.5, respectively, being the fifth most 
common type of cancer among men in Portugal. It is estimated that in Portugal the number of 
new cases 23,400 for males and 5,400 for females; cancer deaths due to bladder cancer are 6,600 
for males and 2,000 for females (Ferlay et al. 2013). Although the improvement in medical care 
and prevention, it is still a widely spread disease worldwide, with incidence and mortality variable 
across countries and between sexes. Bladder cancer is mostly diagnosed in patients over 50 years 
old, although it can manifest at any age. Most of the patients diagnosed with bladder cancer 
remain non-muscle invasive or superficial (Bryan et al. 2010). Although the existing data for 
recurrence after treatment of bladder cancer are conflicting, variating from 15% to 80% at 1 year, 
some aspects are known: bladder cancer re-incidence tends to increase from 1 to 5 years after 
treatment and most of the patients that present recurrence will develop distant metastases 
(Soukup et al. 2012; Van Den Bosch & Witjes 2011).  
The bladder is a hollow organ shaped like a balloon located in the lower abdomen just 
above and behind the pelvic bone. Due to its main function (urine storage), it has muscular and 
flexible walls. The urinary bladder wall is lined with transitional cells (transitional epithelium or 
urothelium) and squamous cells. Next to urothelium is a layer of loose connective tissue, called 
lamina propria, which is covered by three indistinctively separated layers of smooth muscle.  
Outside these three layers is a fat layer that lines and protects the bladder (Fig. 1) (Assefa & Yosief 
2003; Saladin 2008).  
Bladder cancer progression is characterized by four stages (Fig. 1). The stage of a bladder 
cancer describes how far it has spread. It can be confined to the lining of the bladder (early stage) 
or it can spread to lymph nodes near the bladder or spread to nearby organs (invasive).  
Stage 0 tumors arising in the urothelium can spread to the lamina propria layer (stage I). 
Until this degree they are called superficial bladder cancers or non-muscle invasive. As cancer 
grows and invades the muscle layer of the bladder wall originates a muscle invasive cancer (stage 
II). It can further extend beyond the bladder muscle and into the outer layer (stage III) or further 
spreading toward the abdominal or pelvic wall (stage IV). Muscle invasive cancers after stage IV 
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may start to invade nearby organs, usually the uterus or vagina in women or the prostate gland in 
men, and possibly invade the wall of the abdomen. At this point, when bladder cancer 
invasiveness is at its maximum, cancer cells can start to be found in nearby lymph nodes as in 
other organs. This process of invasion of other organs from the original place/organ is called 
metastasis (Bryan et al. 2010; Park et al. 2014). 
 
Figure 1. Bladder layers and bladder cancer progression (non-invasive tumours: stages CIS, Ta 
and T1; invasive tumours: T2-4) Adapted from (http://www.cancerresearchuk.org/) 
 
The most commonly used system of classification of tumor penetration degree is the 
American Joint Committee on Cancer (AJCC) Tumor-Node-Metastases system (TNM) based in 
three key categories (T, N and M) subdivided according to invasiveness. In either stage X 
represents lack of information to be assessed a diagnostic, and 0 absence of cancer to those 
categories. According to this classification system, T describes how far the primary tumor has 
grown, being a Ta a non-invasive papillary carcinoma, low grade tumors; and a Tis being a high 
grade non-invasive flat carcinoma (flat carcinoma in situ, or CIS). Tis are difficult to remove and if 
left untreated will progress to muscle invasive. When it progresses to the lamina propria it is then 
classified as a T1. After invading the muscle layer, it is a T2 tumor, subdivided in T2a and T2b if it 
has grown to the inner or outer half of the muscle layer, respectively.  After invading the fat layer 
surrounding the bladder is classified as a T3, if only visible microscopically a T3a, or if large 
enough to be seen or sensed by a surgeon or medical imaging. Further progress to the 
surrounding organs is categorized as T4, further divided as a T4a when spreading to prostate 
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(men) or to the uterus and/or vagina (women), or as a T4b when spreading to the pelvic or 
abdominal walls. N categories describes spreading only to near lymph nodes, being divided in N1 
to a single lymph node affected in the pelvis, N2 to two or more affected lymph nodes, and N3 
when the cancer spreads to lymph nodes along the iliac artery. The final categorizing stage M 
represents the absence, M0, or presence, M1, of metastasis in other places/organs (Bryan et al. 
2010; Park et al. 2014; Tanaka et al. 2011; Thompson et al. 2015; Egner 2010). 
Combining these categories (T, N and M) and bladder cancer stages (I to IV), the overall 
cancer stage can be determined. The main overall stages are 0a (Ta, N0, M0); 0is (Tis, N0, M0); 
stage I (T1, N0, M0); stage II (T2a or T2b, N0, M0); stage III (T3a, T3b or T4a, N0, M0). Stage IV is 
composed of any cancer T4b and/or since the cancer starts invading nearby lymph nodes or 
metastasis to other parts of the body (Egner 2010).  
The most common treatment for bladder cancer is transurethral resection and intravesical 
therapy. Cystoscopy, urine cytology, excretory urograms and medical imaging as used for bladder 
cancer diagnosis. However, the success in the immediate treatment of these disease is 
overshadowed by the high recurrence rates and tumor understaging, many times due to 
ineffective or incorrect performed surgery and tumor evaluation (Bryan et al. 2010; Soukup et al. 
2012; Van Den Bosch & Witjes 2011).  
 
1.1.1 Bladder cancer treatment 
The conventional treatments of bladder cancer include radical cystectomy and 
transurethral resection, followed by radiation therapy and systemic chemotherapy (trimodality 
therapy). Radical cystectomy has been considered the gold-standard treatment for muscle-
invasive bladder cancer and involves removal of the bladder and prostate in men and anterior 
exenteration (bladder, uterus, ovaries, and part of vagina) for women (Chedgy et al. 2016). 
Combined treatment approaches comprising transurethral resection of the bladder tumor and 
intravesical therapy present a compelling alternative to radical cystectomy (Bekelman et al. 2013). 
However, these conventional approaches might cause unwanted side effects and in some cases 
they are not totally effective (Witjes et al. 2010).  Therefore, there is a pressing need for the 
development of anticancer drugs targeting the bladder cancer cells, while sparing normal 
surround tissue and limiting side effects.  
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1.2 Photodynamic Treatment (PDT) 
Photodynamic Therapy (PDT) is a therapeutic approach that involves three main 
components: a non-toxic photo active drug called photosensitizer (PS), a harmless light source 
with particular wavelength, and the production of reactive molecular oxygen in the target tissue 
(Castano et al. 2004). After selective accumulation in cancer cells, irradiation of the tumor with a 
light source with specific wavelength induces the excitation of the PS from a ground-state to an 
excited singlet state, 1PS*. The excited-singlet-state has a very low half-life time (between 10-6 
seconds and 10-9 seconds), being extremely unstable, which can decay back to the its ground-
state emitting fluorescence (Celli et al. 2003). However, the PDT effect is obtained when 1PS* 
undergoes intersystem crossover to an electronically different excited state, the excited-triplet 
state, 3PS* (Fig. 2) (Calin & Parasca 2006; Luksiene 2003). As 3PS* has longer life time than the 
singlet-state, the cytotoxic effects of PDT are usually mediated by that state. 3PS* can either 
directly react with the substrate creating radical ions that will interact with molecular oxygen 
producing reactive oxygen species (type I reaction) or react with the surrounding molecular 
oxygen producing a reactive cytotoxic form of oxygen, singlet oxygen (type II reaction) as the 
primary photochemical product (Castano et al. 2004; Foote 1991; Celli et al. 2003). Type-I 
photochemical reactions often result in the formation of superoxide anion by the transfer of an 
electron from the PS to molecular oxygen. Although superoxide anion is not a very reactive 
oxygen species in biological systems, it can react to induce hydrogen peroxide (H2O2) production, 
which can easily cross biological membranes, inducing cellular damage (Bergamini et al. 2004; 
Sharman et al. 2000). 
 
Figure 2. PDT Principle under photo-physical and -chemical points of view 
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In order to ensure adequate PS excitation and tissue penetration, it is essential to choose 
a suitable source for PDT. Wavelengths in the visible light, between 400 and 800 nm, can induce 
relevant cellular responses to PDT (Celli et al. 2003).  Due to blue light penetrates less efficiently 
through tissue than red and infrared radiations, the maximum absorption of the PS for PDT should 
correspond to the window between 650-850 nm, where penetration of light into tissue is quite 
high and the energy of the triplet state is enough for singlet oxygen production (Plaetzer et al. 
2009). 
 First reports of the PDT principle have been found to date back as much as 3,500 years 
ago in ancient cultures such as in Egypt, Greece and India, were a mixture of herbs followed by 
exposure to sunlight was used to treat many skin diseases such as skin depigmentation. These 
reports can be found around ancient cultures, but PDT as a treatment practically disappeared 
from the world since ancient times having remerged in the final 1890, early 1900. Since then PDT 
has been found to be a viable treatment to various maladies: acne, wet age-related macular 
degeneration (AMD), psoriasis, herpes, malignant forms of cancer in bladder, lungs, head, neck 
and particularly skin. Its first use in the treatment of cancer was described in 1903 by von 
Tappeiner and Jesionek were preliminary results using eosin applied to basal carcinoma cells prior 
to irradiation (Jodlbauer & Von Tappeiner 1904). In parallel, in 1913, Meyer-Betz started studying 
a class of PS called porphyrins, using the substance Hematoporphyrin to treat rat tumours and 
going as far as self-administrate and expose the administrated area to sun light resulting in 
swelling and burning sensation due to phototoxic reaction induced by the activation of the PS  
(Meyer-Betz 1913).  
Compared to other forms of treatment, PDT is a preferable treatment to various maladies. 
In bladder cancer for example, due to its translucent tissue, geometry, allowing symmetrical light 
distribution, and easy access through endoscopy associated with newer light delivery catheters, 
bladder is an organ that possesses a high potential to be a suitable target for this therapy, in 
opposition to currently existing therapies that have higher risks. Nevertheless, PDT has its 
disadvantages. The promising use of PDT in order to cure a panoply of diseases has instigated its 
research in order to improve it in order to be used as a viable and more widely spread therapy 
(Luksiene 2003). 
 
Since its first medical application in the treatment of cancer, a continuous struggle has 
been fought in order to found better and powerful PSs that could gather the desirable 
characteristics to pharmaceutical administration and safely used in human cancer treatment. In 
6 
 
this field, researchers continuously try to design and synthesize new PSs as potential therapeutic 
agents in cancer treatment. However, to date, none of the PS available on the market exhibit only 
accumulation in the cancer cells, and their uptake by non-cancerous cells cannot completely be 
avoided (MacDonald & Dougherty 2001). Therefore, the choice of a suitable PS, along with a 
compatible light source are key components in PDT.  
The development of an “ideal” PS for PDT should meet the following criteria (Pushpan et 
al. 2002): (i) available in pure form with known chemical composition; (ii) photostable and soluble 
in aqueous media; (iii) strong absorption in the red region of the electromagnetic spectrum (680-
800 nm); (iv) lack of dark toxicity of the PS and its metabolites; (v) high phototoxicity via high 
singlet oxygen quantum yield; (vi) specific accumulation in cancer cells; (vi) easy administration; 
(vii) rapid elimination (pharmacokinetics) after PDT application, in order to minimize the risk of 
photosensitivity or other unwanted secondary effects. The specific nature of an ideal 
photosensitizer instigates research in order to create the best ones. 
 
1.2.1 First, second and third generation PSs 
Due to number of characteristics that an ideal PS must possess, different kinds of PSs have 
been developed over the years. PSs can be divided in first, second and third-generation PSs. The 
great majority of these pharmaceuticals are either porphyrin, derivatives or related compounds. 
Porphyrins are heterocyclic macrocycle organic compounds with an aromatic ring that can be 
naturally found, one of the most well-known examples is heme, co-factor of hemoglobin that 
gives the pigmentation to red blood cells. The absorption spectra of these compounds is 
composed of one strong absorption band, called Soret band (around 400 nm) and four 
progressively smaller bands, called Q bands, for the free base derivatives (Bonnett & Berenbaum 
1989). 
First Generation PSs were based upon hematoporphyrin (Hp), an endogenous porphyrin, 
and its derivative (HpD). The first approved PS in the medical treatment of cancer was Photofrin in 
Canada (1993) for the treatment of bladder cancer. Since then, over 120 countries, including 
Portugal, approved the use of Photofrin for the treatment of different maladies as superficial 
bladder cancer, non-small cell lung cancer, esophageal carcinoma, gastric, cervical and 
endobronchial cancers (O’Connor et al. 2009). Although clinically approved, first generation PSs 
possess a huge setback as they induce high photosensitivity in the patient that could last weeks 
after treatment. Other disadvantages can be pointed as the non-selective accumulation in the 
target cells due to low specificity and the low penetration rate of only 5 mm due to the longest-
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wave absorption band with low extinction coefficient (630 nm), allowing only the treatment of 
the most superficial diseases (Meyer-Betz 1913; O’Connor et al. 2009). To date, Photofrin is 
considered the gold standard for PDT. 
 
Second Generation PSs appeared to overcome these disadvantages. PSs with new and 
improved properties were developed based on Photofrin. As examples of second generation PSs 
are benzoporphyrin derivates, chlorins, phthalocyanines, texaphyrins and naturally occurring 
compounds as hypericin and protoporphyrin IX.  These compounds present an increased tissue 
penetration compared to first generation PSs, with strong absorbance in the red and near-
infrared regions (600-800 nm) opposed to first generation allowing the treatment of deeper 
tumors. Although the improvements in comparison to first generation, these second generation 
PSs still possess a disadvantage as they do not present a localized distribution in the target area 
and have low selectivity to tumorous cells (Castano et al. 2004; O’Connor et al. 2009). 
 
In order to oppose the setbacks of previous generations, researches started to study new 
forms of delivering and increase selectivity using first and second generation PSs. Using these 
prior generations and introducing or conjugating them with biochemical devices that would 
provide them improved target specificity, third generation PSs appeared with the most promising 
results to date. Many approaches have been used by researchers in order to increase PSs 
specificity to cancer cells. Although delivering systems, such as liposomes and nanoparticles, can 
improve their accumulation in tumors, both biomolecules with specificity for proteins 
overexpressed in tumors cells or conjugation of monoclonal antibodies directed against tumor 
antigens, have been shown promising results (Bugaj 2011).  
Galactose-binding proteins (i.e. galectin-1 and galectin-3) and glucose transporters (i.e. 
GLUT1) are overexpressed in several types of cancers. The conjugation of sugars such as 
galactose, mannose or glucose to a porphyrinoid is then a valuable way to enhance the selectivity 
of the PS to tumour tissues (David 2010).  Furthermore, the conjugation of carbohydrate targeting 
moieties gives the possibility of tuning the PS macrocycle amphiphilicity (Wojtyk et al. 2006). 
 
1.2.2 Cell Death in PDT 
The photodamage induced by PDT is a result of direct cytotoxic effects (Buytaert et al. 
2008), vascular damage (Chen et al. 2002) and the induction of an immunity response (Garg et al. 
2010). 
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Although PDT can mediate several cell signalling events, its ultimate purpose is to induce 
cell death. The mechanisms that mediate cell death after PDT have long been the subject of 
various studies. The mode and extent of cell death are influenced by several factors, including the 
concentration, physicochemical properties and subcellular localization of the PS, oxygen 
concentration, the intensity of light irradiation and cell type (Pereira et al. 2015) 
When PS is activated with light at specific wavelengths photochemical reactions can lead 
to ROS production and cell damage by oxidizing and degrading cell components (Pereira et al. 
2015). If cell repair mechanisms fail, damaged cells can then activate death signalling pathways. 
Under PDT, cells can undergo death by apoptosis, necrosis or autophagy (Silva et al. 2010; Gomer 
et al. 1988; Agarwal et al. 1993; Oleinick & Evans 1998; Separovic et al. 2011). 
ROS produced after PDT have a short lifetime, acting in the vicinity to their site of 
generation. Therefore, subcellular localization of the PS determines the target of the primary 
damage. Subcellular locations of PS-induced ROS can be diverse, being the most described the 
endoplasmic reticulum, the mitochondria, lysosomes, plasmatic membrane, Golgi apparatus and 
PS binding directly to Bcl-2. The intrinsic web of events triggered after PDT, directly or indirectly, 
induces various changes in the cell signalling that can induce cell death. The main  mechanisms 
involved in PDT efficiency are (1) the increase of the level of intracellular calcium; (2) 
phospholipases activation that lead to cell apoptosis; (3) the decrease of signal transduction of 
cell survival and cancer proliferation receptors; (4) activation of genes associated to apoptosis; (5) 
inducing over or under-expression of cytokines associated to inflammation and haematopoiesis; 
(6) inducing hypoxia through the consumption of molecular oxygen leading to stagnation of 
oxygen in the tumor region; (7) induction of stress related proteins and (8) alterations in cellular 
adhesion proteins (Robertson et al. 2009). The changes in cellular adhesion proteins are one of 
the most important consequences of PDT, as these changes will strongly affect cell behaviour, 
shape and the adhesion of tumor cells between themselves and to the substratum. Cell adhesion 
to the substratum is mediated by integrins and other cellular adhesion molecules that connect the 
extracellular matrix to the intracellular actin cytoskeleton (Tanaka et al. 2011). In that way, it is of 
interest to understand how the cytoskeleton is affected by PDT. In cancer metastasis, cell 
migration and invasion play a decisive role involving dissolution of the cellular matrix surrounding 
the cells, attachment of leading edge, detachment of the adhesions at the trailing edge of the cell, 
and cell contraction by myosin motifs inserting between F-actin filament bundles (Ridley 2003). 
These motility of the cells, only available thanks to the action of cytoskeletal structures that suffer 
continuous polymerization and depolymerisation, makes it one of the targets of interest in 
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photodynamic survival studies and in order to understand how inducing changes in this seemingly 
vital structures will affect the treatment outcome. 
 
1.2.3 Changes in cytoskeleton induced by PDT 
The three major cytoskeleton components presently known to be affected by PDT are 
microtubules (tubulin), intermediate filaments (vimentin) and actin filaments, being the later the 
one that shows more PDT-induced alterations across different cancer types and PSs and 
alterations in these components have been associated to tumor progression and metastasis 
(Vonarx et al. 1995). Due to the highly reported and spread alteration in actin filaments after PDT 
it is believed they play a central role in the early stage effects of phototherapy that eventually 
lead to cell death (Venosa 2015). These alterations are usually accompanied by changes in cell 
shape and morphology. But as previous described, the effects and activation of specific molecular 
pathways induced by PDT are highly dependent on several factors, such as cell type, fluence rate 
and specific PS (Venosa 2015).  
Actin filaments are the structures most reported to be altered in response to PDT. The 
most reported alterations reported are changes in stress fibers, but with many conflicting results. 
Although some report increasing, others report a reduction of stress fibers after PDT. Another 
common effect is the redistribution of actin across the cell. But, as previously referred, for 
different cell lines and PSs, the effects observed greatly vary. Disorganization of original 
conformation of actin filaments seems to be one of the few common factors as loss of actin 
filaments  (Tanaka et al. 2011; Lee et al. 1995; Uzdensky et al. 2005; Casas et al. 2008). 
Microtubules are one of the structures that maintain cellular integrity and are involved in 
several homeostasis related processes but mainly in the establishment and maintenance of cell 
morphology. Microtubules are composed by two main types of tubulin, α and β, that combine to 
form dimeric structures that form the microtubule. Microtubule alterations after PDT have been 
previously reported. As a specific response to a PS, while vimentin intermediate filaments and 
actin stress fiber remained unaltered, it was reported that endoplasmic reticulum motility was 
inhibited as a result of the disruption of microtubules (Lee et al. 1995). Other studies suggest that 
the disruption of microtubules may stimulate the formation of stress fibers and the assembly of 
adhesion plaques. Other studies reported that in response to 5-aminolevulinic acid (ALA) PDT in 
two different cancer cell lines, the microtubules behaviour was distinct, while in one cell line 
microtubules remained practically unchanged, the other responded by the retraction of some 
cells and forming extracellular blebs of tubulin (Uzdensky et al. 2005). 
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Intermediate filaments (IF) are constituted by a multitude of different fibrous proteins, 
mostly vimentin in cells with mesenchymal origin, possessing mainly a structural function and 
giving mechanical stability to animal cells. IF are one of the less studied structures affected by 
PDT. It is known that the main component of IF, the protein vimentin, is degraded as a response 
to various inducers of apoptosis. In a study where a caspase resistant vimentin was transfected 
into cells, a partial suppression and delay of apoptosis PDT-induced was reported, suggesting an 
increased resistance by impairment of caspase-3 translocation (Belichenko et al. 2001). 
 Although cytoskeleton alterations have been widely reported after PDT, these alterations 
are highly variable with different outcomes for different cell lines suggesting that a deeper 
analysis of the complicated web of changes in the cytoskeleton has to be performed. Cytoskeleton 
alterations are known to have a strong effect over the processes leading to cell death. However, 
these alterations are believed to be correlated not only with cancer metastasis and invasiveness, 
but also with the development of PDT resistance (Robertson et al. 2009; Almeida et al. 2004; 
Tanaka et al. 2011). Many studies have been performed not only in order to identify why and how 
these changes occur, but also what other factors are associated to these alterations and how do 
they influence the treatment outcome.   
Besides cytoskeletal and adhesion proteins, many other factors have been reported to 
have an important role in alterations induced after PDT. One protein of interest is RhoA. 
Belonging to the RhoA GTPases family, it is known that it is involved with a multitude of cellular 
processes including, but not limited to, cell division, actin cytoskeleton regulation and induction of 
formation of stress fibers and focal adhesion points. However, there is scarce information 
concerning whether disorganization of actin stress fibers after PDT is correlated with changes in 
RhoA protein levels. 
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Chapter 2. Objectives 
Bladder cancer is a common malignancy in the urinary tract that has a high recurrence 
rate. Although the management of bladder cancer has significantly improved in the past years, 
the treatments available are not totally effective. It is of utmost importance the development of 
novel and more effective approaches to treat bladder cancer. 
PDT consists of three individually nontoxic components - photosensitizer, light and 
molecular oxygen. However, when together they initiate a photochemical reaction leading to the 
generation of ROS. Cytotoxicity and cell death via apoptosis, necrosis or autophagy can occur via 
ROS. Several reports in the literature have shown that cell death pathway induced by PDT 
depends, among other factors, on the PS and its intracellular localization. Third generation PS 
coupled to galactose sugar seem to be interesting for research purposes since cancer tissues 
exhibit overexpression of certain galactose-binding proteins (Thijssen et al. 2015; Yau et al. 2015) 
increasing their specificity/uptake in cancer cells and reducing the unwanted phototoxicity in the 
neighbouring healthy tissues. 
PDT for bladder cancer remains largely investigational having limited clinical use. We have 
previously reported PorGal8, a galactodendritic porphyrin, as a new a water soluble third 
generation PS, able to generate ROS after photoactivation (Fig. 3) (Silva et al. 2012). In fact, 
PorGal8 exhibits very interesting features as a PS: good aqueous solubility, without formation of 
aggregates up to 19 µM; with characteristic absorption spectra of porphyrins, high photo stability; 
demonstrated positive interaction with human serum albumin and positive oxygen singlet 
generation, suggesting that PorGal8 has high potential as a PDT agent.  
 
Figure 3. Schematic representation of PorGal8, a porphyrin conjugated with four dimeric 
structures of galactose (Silva et al. 2012) 
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More recently, we have validated PorGal8 as a novel therapeutic agent for the treatment 
of tumors containing high levels of galactose-binding proteins, namely galectin-1 (Pereira et al. 
2016). We have shown a specific uptake of this PS and induction of ROS-mediated cell death. We 
have also validated the photodynamic efficiency of PorGal8 in an immunodeficient animal model 
bearing subcutaneously implanted a bladder cancer xenograft, overexpressing galectin-1 protein.  
Despite it is known that cell death mechanisms induced after PDT can instigate changes 
and reorganization on the main cytoskeletal components (microtubules, microfilaments and 
intermediate filaments), little is known about the underlying mechanisms.  
The main goal of this work is to investigate whether the phototoxicity induced by PorGal8 
is correlated with alterations in cytoskeletal structures of cancer cells. 
 
In order to accomplish this, we propose to: 
- Evaluate cellular uptake and phototoxicity effects of the PorGal8 in two bladder cancer 
cell lines, UM-UC-3 and HT-1376. 
- Investigate changes in the levels and subcellular redistribution of cytoskeleton 
components - microtubules, microfilaments and intermediate filaments - after PDT with PorGal8. 
- Investigate the role of RhoA in cytoskeleton disorganization after PorGal8-PDT. 
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Chapter 3. Materials and Methods 
3.1 Preparation of PorGal8 working solution 
A porphyrin conjugated with dendritic units of galactose (PorGal8) was synthesized and 
characterized in the “Porphyrins and Phthalocyanines Materials Research Group”, Department of 
Chemistry, University of Aveiro, Portugal (Silva et al. 2012).  
Stock solutions of the PorGal8 at a concentration of 2 mM were prepared in dimethyl 
sulfoxide (DMSO, Sigma Ref. D2650). After solubilization at 35 kHz for approximately forty 
minutes in an ultrasonic bath (Sonorex, TK52, Bandelin), stock solutions were stored at 0-4 °C in 
dark conditions. Freshly working solutions were prepared from stock solution in sterile 
phosphate-buffered saline (PBS, 137 mM NaCl, 27 mM KCl, 81 mM Na2HPO4, 15 mM KH2PO4, pH 
7.30), accounting their water solubility range. The concentration of DMSO was always lower than 
0.5% (v/v), in the working solutions. 
 
3.2 Cell Culture 
The cell lines from transitional cell carcinoma of human urinary bladder were obtained 
from the American Type Culture Collection. UM-UC-3 (ATCC Number: CRL-1749TM) cell line with 
epithelial-like characteristics was derived from a high grade invasive bladder carcinoma of a male 
patient. HT-1376 (ATCC Number: CRL-1472TM) cell line was derived from a 58 years old caucasian 
female with a grade 3 carcinoma of the bladder.  
UM-UC-3 and HT-1376 grown in monolayer were cultured in Roswell Park Memorial 
Institute (RPMI)-1640 medium (Sigma-Aldrich, Ref. R4130), supplemented with 2 g/L sodium 
bicarbonate (Sigma-Aldrich, Ref. S5761), 10% (v/v) heat-inactivated Fetal Bovine Serum (FBS; 
Gibco, Ref. 10270-106), 1% (v/v) antibiotic/antimycotic containing penicillin, streptomycin and 
amphotericin B (Sigma-Aldrich , Ref. 15240-062) and 2mM L-Glutamine (BioWest, Ref. X0550-
100), at 37 °C in a humidified atmosphere with 5% CO2 and 95% of air. Cells were subcultured one 
to three times a week when they reached approximately 80% of confluence.  To check cell 
viability before plating the cells for the experiments, they were trypsinized and resuspended in 
medium. Then, a mixture of cell suspension and trypan blue stain (1:1) was prepared to count the 
cells on a Neubauer chamber. The percentage of viable cells and the concentration of viable cells 
per milliliter of cell suspension were calculated. Only cells with a viability above 90% were used in 
all experiments. 
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3.3 Determination of total protein concentration 
The protein concentration in cell extracts was measured spectrophotometrically using the 
BCA assay kit (BCA/Smith Assay; Pierce, Ref. 23227) using bovine serum albumin as a standard in a 
96-well cell culture plate (Orange Scientific). This procedure involves two steps: the first is the 
biuret reaction in an alkaline environment, whose faint blue colour results from the reduction of 
cupric ion (Cu2+) to cuprous ion (Cu1+) by peptide bonds in protein, therefore, the amount of 
reduced Cu2+ is proportional to the amount of protein present in the solution. The second step is 
the chelation of two molecules of BCA with one cuprous ion using the reagent containing 
bicinchoninic acid, resulting in a water-soluble complex product with intense purple colour that 
strongly absorbs light at the wavelength of 562 nm.  
 
i) Determination of total protein concentration for cellular uptake of PorGal8 assay (cells 
solubilized in 1% (m/v) SDS solution in PBS pH 7.0) 
In a 96-wells plate, the following solutions were pipetted into each well: 25 μL of sample 
buffer (1% (m/v) SDS (sodium dodecyl sulphate, Biorad Ref. 161-0301-100g) in PBS (pH 7.0)); 25 
μL of sample, blank (sample buffer), BSA standard (prepared in the sample buffer at 
concentrations ranging from 12.5 - 800 μg.mL-1 prepared from the BSA standard at 2 mg.mL-1); 
and 200 μL of BCA working Reagent (fifty parts of BCA reagent A mixed with one part of BCA 
reagent B).  
 
ii) Determination of total protein concentration for Western blot analysis (cells 
solubilized in RIPA buffer) 
In a 96-wells plate, the following solutions were pipetted to each well: 25 μL of sample 
buffer (RIPA buffer: 150 mM NaCl, 50 mM Tris base, 5 mM EGTA, 0.5% (m/v) DOC, 0.1% (m/v) 
SDS, 2 mM PMSF, 2 mM IAD, 1 tablet of protease inhibitor cocktail, pH 7.50); 25 μL of sample 
diluted in RIPA buffer 1:9 (v/v), blank (sample buffer), standard (prepared in the sample buffer at 
concentrations ranging from 12.5 - 800 μg.mL-1 using the BSA standard at 2 mg.mL-1); and 200 μL 
of BCA working Reagent (50 parts of BCA reagent A mixed with one part of BCA reagent B).  
 
The plate was incubated at 37 °C for 30 min. Then, the absorbance at 570 nm was 
measured on a microplate reader Synergy™ HT (Biotek Instruments) controlled by BioTek's Gen5™ 
Data Analysis Software. The protein concentration in the samples was directly obtained by 
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plotting the average of the absorbance at 570 nm for each BSA standard in function of its 
concentration (μg.mL-1) (Smith et al. 1985). 
 
3.4 Preparation and treatment of cancer cells with PorGal8  
 UM-UC-3 and HT-1376 cells were seeded at a density of approximately 9.4 x 104 cells.cm-2 
in culture plates (Orange Scientific). Twenty-four hours after plating, the culture medium was 
removed and the cells were washed once with sterile PBS. Cells were then incubated with PorGal8 
(in PBS containing < 0.5% (v/v) DMSO) in the dark for ninety minutes. 
 
3.5 Cellular Uptake of PorGal8  
Based on the fluorescence properties of the porphyrin PorGal8, its concentration inside 
the cancer cells can be determined by fluorimetry (after cell lysis) and normalized to total protein 
quantity.  
For this assay, UM-UC-3 and HT-1376 cells were seeded at a density of 3 x 104 cells/well in 
a 96-well culture plates (Orange Scientific) as previously described. After incubation with the 
desired concentrations of PorGal8 in the dark, cells were immediately washed with PBS buffer at 
pH 7.0 and lysed in 120 μL of 1% (m/v) sodium SDS solution in PBS (pH 7.0) with gentle continuous 
agitation on an automatic plate shaker in the dark for 30 min at RT. Ninety μL of this cell 
suspension was transferred to 96-wells black plates and the intracellular fluorescence of PorGal8 
was determined by fluorometric measurement in an microplate reader Synergy™ HT (Biotek 
Instruments), using standard PorGal8 solutions for construction of a calibration curve.  
Fluorescence readings used the excitation and emission filters set at 360/40 nm and 645/40 nm, 
respectively. PorGal8 concentration in the samples was directly obtained by comparison to the 
standard curve and the results were normalized for protein concentration (determined by the 
BCA/Smith assay as previously described). 
 
3.6 Photodynamic assay 
After PorGal8 incubation, the cells were washed once with PBS and covered with fresh 
RPMI-1640 medium. In a dark room, the cells were irradiated for forty minutes with a LEDs array 
system emitting white light with two emission peaks at λ = 450 ± 20 and λ = 550 ± 50 nm. The cell 
culture plates were placed above the LEDs (Fig.4) Under these conditions, most of the light was 
emitted at a potency of 8.4 mW.cm-2. After irradiation, cells were either immediately used for the 
determination of cell uptake of PorGal8 assay or washed once with PBS and incubated with RPMI-
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1640 medium for selected time points (thirty minutes or twenty-four hours depending of the 
assay) in the humidified incubator gassed with 5% CO2 and 95% air. 
The Dark assays were similarly handled to the PDT assay, being kept in the dark in the 
incubator for the forty minutes corresponding to the irradiation treatment. 
 
Figure 4. (Left) Representative image of LED array system and (Right) Emission spectra of the 
LED array system used in the irradiation assays. Composed of a matrix of 24 x 16 LEDs totalizing 
384 light sources emitting white light with two emission peaks at λ = 450 ± 20 and λ = 550 ±50 nm. 
The used regulated Plug-in adaptor with LED indicator 800 mA was purchased from MW.  
 
3.7 Cell viability assays 
The evaluation of the cytotoxicity effects of the PorGal8 was evaluated twenty-four hours 
after incubation with PorGal8 and treatment (dark or irradiated) as previously described. For this 
evaluation two assays were performed: MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-
tetrazolium bromide) colorimetric and Trypan Blue assays. 
 
i) MTT colorimetric assay 
For this assay UM-UC-3 and HT-1376 cells were seeded at a density of 3.0 x 104 cells/well 
in a 96-well culture plates, as previously described. Cell metabolic activity after treatment (dark or 
irradiated), was determined 24 h after treatments by measuring the ability of bladder cancer cells 
to reduce MTT (yellow coloured, Sigma, Ref. M2128-1G) to an insoluble formazan product (with a 
blue purple colour), being this reduction proportional to the mitochondrial enzyme succinate 
dehydrogenase activity. Briefly, twenty four hours after treatment, 50 μL of medium was removed 
and 10 μL of MTT stock solution (3 mg.mL-1 in PBS buffer) was added to each well at a final 
concentration of 0.5 mg.mL-1. The plates were then incubated in the darkness at 37 °C for 2 hours. 
The resulting purple needle-shaped crystals were dissolved by the addition of 150 μL acidic 
isopropanol (0.04 M HCl in absolute isopropanol). To solubilize completely the converted dye, 
repetitive pipetting was applied. The absorbance was measured at 570 nm (using 620 nm as the 
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background wavelength), using a microplate reader (Synergy HT, Biotek). The data were 
expressed in percentage of control (untreated cells) (Mosmann 1983). 
 
 For each well, the absorbance was expressed as: 
 
The results were expressed as percentage of MTT reduction: 
 
 
ii) Trypan Blue dye exclusion   
The UM-UC-3 and HT-1376 cells were plated at a density of 8.9 x 104 cells/ well (250 μL), 
in 48-wells culture plates, as previously described. Cell membrane integrity after PorGal8 
incubation, was determined 24 h after treatment (dark or irradiated) by trypan blue dye exclusion 
assay. Once trypsinized, an aliquot of the cellular suspension was diluted in the trypan blue stain 
(1:1) and the cells were counted for determination of both viable and nonviable cells. The organic 
amine dye trypan blue would be excluded from viable (living) cells with intact membrane 
appearing bright under the microscope while nonviable cells (cells with compromised membrane 
integrity) would appear stained in blue. 
 
Viable (bright cells) and nonviable cells (cells stained in blue) were counted and summed 
for the total number of cells. The viability was calculated as follows: 
 
The concentration of viable cells per millilitre in the cell suspension was calculated 
considering the average of viable cells per each counting square, the dilution made and the 
volume of each counting square:  
 
3.8 Preparation of Cellular Extracts of UM-UC-3 and HT-1376 cells for Western Blotting 
For immunodetection of proteins, UM-UC-3 and HT-1376 cells were plated at a density of 
8.93 x 105 cells/well (1.5 mL per well), in a 6-well culture plate for 24 h before treatment. The cells 
were then treated with 10 µM PorGal8 (500 μL) and the photodynamic treatment was performed 
as previously described. After treatment, cells were washed once with PBS (500 µL) and incubated 
in RPMI-1640 medium for thirty minutes or twenty-four hours in the humidified incubator gassed 
with 5% CO2 and 95% air. UM-UC-3 and HT-1376 cells were washed once with ice-cold PBS (500 
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μL) and then with ice-cold OVNA 0.5 mM (500 μL; sodium orthovanadate in PBS Buffer, Sigma 
S6508) and lysed with ice-cold RIPA (200 µL; buffer with fresh protease inhibitors). The cell lysates 
were then transferred to microtubes with the help of a rubber policeman (cell scrapper) and 
incubated on ice during 30 min. During incubation, samples were vortexed 10 seconds every 5 
minutes. The total cell lysates were centrifuged at 18,000 x g for 16 minutes, at 4 °C. The 
supernatant was transferred to a new microcentrifuge tube. The supernatants were used for 
protein concentration determination (Smith/BCA Assay) as previously described, followed by 
denaturation with Laemmli buffer 6x (350 mM Tris-HCl, pH 6.8, 30% (m/v) glycerol, 10% (m/v) 
SDS, 600 mM DTT, 0.012% (m/v) bromophenol blue, pH 6.80). Cellular extracts were stored at -20 
°C after denaturation (Laemmli 1970). 
 
3.9 Western Blotting 
3.9.1 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis and Blotting 
 The samples were heated at 37 °C for 30 minutes. Thirty to forty μg of protein samples 
were loaded on polyacrylamide gels and the proteins were separated by electrophoresis. The 
electrophoresis was stopped when the dye front reached the bottom of the gel. Following gel 
electrophoresis, the separated protein mixtures were transferred to a solid support for further 
analysis. The polyvinylidene difluoride membranes (Immun-Blot PVDF membranes, BioRad) were 
first activated with 100% MetOH, and then soaked in Milli-Q water and equilibrated in transfer 
buffer. All the material used in the blotting (sponges, sheets of filter paper), as well as the gels 
were also equilibrated in transfer buffer. The gel and the PVDF membrane were assembled into a 
sandwich along with sheets of filter paper and sponges. The separated proteins were then 
transferred to the PVDF membranes (using ice cold transfer buffer) for 90 min under agitation, 
the tank in ice (and using a cooling coil inside the tank). At the end, the baking of the membranes 
was performed by incubation at 50 °C for 20 min (Towbin et al. 1979). 
 Table 1. Primary Antibodies used in western blotting (WB) and immunocytochemistry (ICC) 
assays 
Antibody Dilution Supplier Ref. 
WB ICC 
Mouse anti β-actin 1 : 20000 --- Sigma-Aldrich A5441 
Mouse anti Vimentin Ab-2 1 : 1000 1 : 250 ThermoFisher MS-129-P1 
Mouse anti α-Tubulin 1 : 1000 1 : 500 Sigma-Aldrich T6199 
Rabbit anti RhoA 1 : 5000 1 : 300 Abcam ab187027 
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3.9.2 Antibodies incubations, detection and quantification 
 The membranes were placed into blocking buffer (5% (v/v) non-fat milk or 3% (v/v) BSA, 
prepared in tris buffer saline tween20 (TBST buffer; 20 mM Tris base, 150 mM NaCl, 0.1% (v/v) 
Tween 20, pH 7.60) for thirty to ninety minutes at RT with gentle agitation. The membranes were 
incubated with the primary antibody, diluted in 2.5% non-fat milk, prepared in TBST), for two 
hours at RT, under low agitation. After incubation, the membranes were rinsed in TBST (3 x 10 
min) at RT. The appropriate secondary antibody conjugated with the enzyme horseradish-
peroxidase diluted 1:10,000 (v/v) in 2.5% non-fat milk (prepared in TBST) was added, and the 
membranes were incubated for one hour at RT, under moderate agitation. After incubation with 
the secondary antibodies, the membranes were washed in TBST (3 x10 min), with agitation. To 
demonstrate equivalent protein loading, all the membranes were re-probed for the protein β-
actin. For the detection, the membranes were placed on the chemiluminescence detection 
system Chemi Doc™ XRS (Bio-Rad) controlled by the software Quantity One (proteins side up), 
incubated with the substrate solution (1:1, by volume, mixture of luminol/enhancer and peroxide 
buffer; Immun-StarTM WesternCTM Chemiluminescent Kit, BioRad) for 1 min following 
manufacturer instructions, and then the images were acquired. The intensity signal of the bands 
was quantified using the software ImageJ 1.6 and the fold change in protein levels were expressed 
as follows and then normalized to the control situation: 
 
 
3.10 Immunofluorescence assays and Confocal Microscopy 
For visualization of the distribution of specific proteins associated to cytoskeleton 
structures (for microtubules tubulin and for intermediate filaments vimentin) and cell death 
(RhoA) through the sample immunocytochemistry assays were performed. For the visualization of 
F-actin filaments staining using Phalloidin–Tetramethylrhodamine B isothiocyanate (TRITC-
conjugated phalloidin; Sigma, Ref. P1951) was performed (Casas et al. 2008).  
One coverslip/well (Warner Instruments) in 24-wells culture plates were coated with poly-
L-lysine (Sigma, Ref. P4707) (80 µL) for 30 to 40 minutes at RT. The poly-L-lysine was removed and 
the coverslips were allowed to completely dry for 30 minutes at RT. The UM-UC-3 and HT-1376 
cells were plated carefully at a density of 1.75 x 105 cells/well (500 µL) for 24 h before treatment. 
After PorGal8 incubation and treatment as previously described the plates were incubated for 
thirty minutes to twenty-four hours after treatment, dark or irradiated. After the incubation 
periods, cells were washed once with PBS.  
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i) Immunocytochemistry Assays (for tubulin, vimentin and rhoA antibodies) 
After washing with PBS, cells were fixed with the appropriate fixator (300 µl) and time 
according to the target protein structure and cell line. For immunostaining with tubulin for both 
UM-UC-3 and HT-1376 cell lines, and vimentin for UM-UC-3 cells, fixation was performed with ice-
cold MES buffer (100mM 2-(N-morphilino)-ethane sulphonic acid, 1 mM EGTA, 1mM MgSO4, 90% 
MetOH (v/v), pH 6.90) during five minutes; HT-1376 cells destined to be immunostained with 
vimentin were fixed with ice-cold MetOH during five minutes; when destined to immunostaining 
with RhoA antibody both cell lines were fixed with PFA 4% (prepared in PBS buffer, pH 7.30) 
during ten minutes. The samples were after fixation washed with PBS (3 x 5 min). The cells were 
treated with permeabilization buffer (1% (v/v) Triton X-100, 0.02% (m/v) BSA, 0.02% (m/v) NaN3, 
prepared in PBS, pH 7.30) (250 µl) during 10 min. Cells were then washed with washing buffer 
((0.02% (m/v) BSA (VWR, Ref. 441554Y), 0.02% (m/v) NaN3, Prepared in PBS, pH 7.30), three times 
each five minutes. The cells were then incubated with the blocking buffer (5% (v/v) BSA, prepared 
in PBS buffer) for 20 min, in a humidified chamber. After blocking, the cells were incubated with 
the primary antibody diluted in washing buffer during ninety minutes at RT, in a humidified 
chamber in the dark. The primary antibody solution was decanted and the samples were washed 
with washing buffer (3 x 5 min). The cells were incubated with the secondary antibody and 4′,6-
Diamidino-2-phenylindole (DAPI, Enzo Life Sciences) (1 μg.mL-1) diluted in washing buffer for sixty 
minutes at RT, in a humidified chamber in the dark. The secondary anti-rabbit or anti-mouse 
antibodies used were the Alexa Fluor 488 Goat Anti-Rabbit and Alexa Fluor 568 Goat Anti-Mouse 
(Molecular Probes). The cells were washed again with the washing buffer (3 x 5 min). The 
coverslips were mounted using the glycergel mounting medium and sealed with nail polish. The 
samples were stored in an appropriate box at 4 °C until acquisition of images by fluorescence 
microscopy (confocal microscope from Zeiss; LSM 710, Carl Zeiss). 
 
ii) F-Actin Staining  
After washing with PBS, cells were fixed with 4% PFA (300 µl) for 30 min at RT. Samples 
were washed with PBS (3 x 5 min), dehydrated with acetone then permebealized with 0.1% Triton 
X-100 (prepared in PBS, 250 µl) and washed again with PBS (3 x 5 min). To visualize actin filaments 
samples were incubated with 50 μg.mL-1 TRICT-conjugated phalloidin and DAPI (1 μg.mL-1) diluted 
in PBS buffer for forty minutes. The samples were again washed with PBS (3 x 5 min). The 
coverslips were mounted using glicergel mounting medium and stored at 4 °C until visualization 
under the fluorescence microscope. 
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Chapter 4. Results 
4.1 PorGal8 accumulates in bladder cancer cells 
Our group previously reported PorGal8, a porphyrin conjugated with dendritic units of 
galactose, as a new and efficient third generation PS for PDT against two bladder cancer cell lines, 
HT-376 and UM-UC-3, which were derived from transitional cell carcinoma (Silva et al. 2012; 
Pereira et al. 2016). The present study was undertaken to investigate whether phototoxicity 
induced by PorGal8 is correlated with alterations in skeletal structures of cancer cells. 
We started to determine the concentration of PorGal8 inside the UM-UC-3 and HT-1376 
cells by spectrofluorimetry, in order to determine the optimum concentration to be used in the 
following assays. Bladder cancer cells were incubated with increasing concentrations (0.5, 2.5, 5, 
10 and 12.5 µM) of PorGal8 in PBS for ninety minutes in the dark. The intracellular concentration 
of PorGal8 was determined using a calibration curve using known concentrations of the PS (Fig. 5).  
 
Figure 5. Intracellular uptake of PorGal8 by UM-UC-3 (A) and HT-1376 (B) bladder cancer cells. 
Cells were incubated in the darkness with increasing concentration of PorGal8 (0.5, 2.5, 5, 10 and 
12.5 µM) for ninety minutes. The concentration of PorGal8 was determined by fluorescence 
spectroscopy and the results were normalized to total protein quantity. Data are the mean value 
± S.E.M. (standard error of mean) of at least three independent experiments performed in 
triplicates. **(p<0.01), ***(p<0.001), **** (p<0.0001) significantly different from control cells 
(incubated with PBS). 
 
The cellular uptake of PorGal8 was concentration-dependent and higher in UM-UC-3 than 
HT-1376 cells. Maximum intracellular accumulation of PorGal8 was achieved when cells were 
incubated between 10 -12.5 µM of the PS. UM-UC-3 and HT-1376 cells incubated for ninety 
minutes with 10 µM PorGal8, presented an intracellular concentration of 3068 ± 333 and 549 ± 
109.9 nmol PorGal8 per mg of protein, respectively (Fig. 5A and B).  
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4.2 PorGal8 induces phototoxicity in bladder cancer cells 
After confirmation of PorGal8 uptake by bladder cancer cell lines, its cytotoxicity in the 
dark was assessed 24 h after treatment by MTT and Trypan Blue assays. No dark toxicity was 
observed in untreated cells (up to ninety minutes) in the presence of 0.5% DMSO in PBS.  In both 
cell lines, incubation with 10 µM PorGal8 in the dark did not induce toxicity (Fig. 6A, B, C and D). To 
test the effect of light irradiation (white light LED system, delivered at 8.4 mW.cm-2 for forty min) 
immediately after PorGal8 uptake, cell viability assays were also performed 24 h after treatment. 
White irradiation of cells (previously incubated with PBS containing 0.5% DMSO for ninety min in 
the dark) per se did not induce toxicity (data not shown). However, when both cell lines were 
incubated with 10 µM PorGal8 and then irradiated, there was an increased phototoxicity.  
When cells were incubated with 10 µM PorGal8 for ninety min and then irradiated, a 
significant decrease in cell viability was observed. The phototoxicity was higher in UM-UC-3 cells 
than in HT-1376 cells. Photoactivation of 10 µM PorGal8 induced a decrease in MTT reduction, 
from 100% to 53.62 ± 5.93 (p<0.001) in UM-UC-3 cells and to 80.33 ± 8.26 (p<0.05) in HT-1376 
cells (Fig. 6A and C). Trypan blue exclusion assay was used to confirm viability results obtained by 
MTT. Photoactivation of 10 µM PorGal8 induced a decrease in the percentage of excluded dye, 
from 100% to 57.07 ± 9.25 (p<0.0001) in UM-UC-3 cells and to 76.84 ± 4.68 (p<0.0001) in HT-1376 
cells (Fig. 6B and D). 
 
Figure 6. PorGal8 is nontoxic in darkness and induces toxicity after its photoactivation in UM-
UC-3 (A, B) and HT-1376 (C, D) cells. Cells were incubated with 10 µM PorGal8 incubation in dark 
23 
 
conditions for ninety min. Cell viability was evaluated 24 hours after treatment (dark or after 
irradiation with 8.4 mW.cm-2 for 40 min) using the MTT colorimetric (A, C) and Trypan Blue assays 
(B, D) in UM-UC-3 and HT-1376 cell lines. The percentage of toxicity was calculated relatively to 
control cells (cells incubated with PBS). MTT reduction data (A and C) is presented as the mean ± 
S.E.M of at least two independent experiments (dark conditions) and four independent 
experiments (after irradiation) performed in triplicates. Not significantly different from control 
cells in dark assays. *(p<0.05), ***(p<0.001) significantly different from control cells. For trypan 
blue assays data (B and D) is presented as the mean ± S.E.M. of one independent experiment in 
sextuplicates (dark treatment) and three independent experiments in triplicates (irradiation 
treatment). *(p<0.05), **** (p<0.0001) significantly different from control cells.  
 
4.3 Cytoskeleton disorganization after PDT with PorGal8  
To evaluate whether cell death induced by PDT with PorGal8 is associated with changes in 
cytoskeleton, its three major components – microtubules, microfilaments and intermediate 
filaments - were evaluated 30 min or 24 h after treatment, by Western Blotting and/or 
fluorescence microscopy.  
PorGal8 did not induce any significant changes in the protein levels of α-tubulin, which is 
one of the main constituents of the microtubules, 30 min or 24 h after PDT in UM-UC-3 (Fig. 7).  
 
Figure 7. PorGal8 does not induce changes in α-tubulin protein levels after photodynamic 
activation in UM-UC-3 cells. Western blot analysis and quantification of α-tubulin protein levels in 
UM-UC-3 cells 30 min and 24 h after irradiation. β-actin was blotted as loading control. 
Quantitative analysis of α-tubulin (normalized to β-actin) expressed as ratio to controls (cells 
incubated with PBS instead of PorGal8) in UM-UC-3 cell line. Data represents the mean ± S.E.M. of 
at least four independent experiments. 
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Figure 8. PorGal8 reduces α-tubulin protein levels after photodynamic activation in HT-1376 
cells. Western blot analysis and quantification of α-tubulin protein levels in HT-1376 cells 30 min 
and 24 h after irradiation. β-actin was blotted as loading control. Quantitative analysis of α-
tubulin (normalized to β-actin) expressed as ratio to controls (cells incubated with PBS instead of 
PorGal8) in the HT-1376 cell line. Data represents the mean ± S.E.M. of at least four independent 
experiments. **(p<0.01) significantly different 24 h after PorGal8-PDT from control cells in HT-
1376 cell line. 
 
Figure 9. Changes of α-tubulin in HT-1376 cells 30 min and 24 h after targeted PDT with PorGal8. 
Immunofluorescence detection of α-tubulin (red). The nuclei were stained with DAPI (blue). Scale 
bars 20 m. 
Although no significant changes in the protein levels of α-tubulin 30 min after treatment 
were detected, a significant decrease in α-tubulin protein content was observed 24 h after PDT in 
HT-1376 cells (Fig. 8). Control HT-1376 cells presented well-organized microtubule networks 
within cell´s cytoplasm. In contrast, PDT-treated HT-1376 cells displayed a rearrangement of 
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microtubule networks to a round shape and disorganized microtubules 30 min after irradiation. 
After 24 h, although a few cells showed a recovery in microtubules organization, the fluorescence 
intensity decreased noticeably in most of the cells (Fig. 9).  
PorGal8 did not induce any significant changes in the protein levels of vimentin in UM-UC-
3 and HT-1376 cells 30 min after PDT. However, 24 hours after irradiation both cell lines 
presented a reduction in the protein levels of vimentin (Figs. 10 and 11). 
 
Figure 10. PorGal8 induces changes in vimentin protein levels after photodynamic activation in 
UM-UC-3 cells. Western blot analysis and quantification of vimentin protein levels in UM-UC-3 
cells 30 min and 24 h after irradiation. β-actin was blotted as loading control. Quantitative 
analysis of vimentin (normalized to β-actin) expressed as ratio to controls (cells incubated with 
PBS instead of PorGal8) in UM-UC-3 cell line. Data represents the mean ± S.E.M. of at least three 
independent experiments. ***(p<0.001) significantly different from control cells in UM-UC-3 cell 
line twenty-four hours after PorGal8-irradiation.  
 
Figure 11. PorGal8 reduces vimentin protein levels after photodynamic activation in HT-1376 
cells. Western blot analysis and quantification of vimentin protein levels in HT-1376 cells 30 min 
and 24 h after irradiation. β-actin was blotted as loading control. Quantitative analysis of vimentin 
(normalized to β-actin) expressed as ratio to controls (cells incubated with PBS instead of PorGal8) 
in the HT-1376 cell line.  Data represents the mean ± S.E.M. of at least five independent 
experiments. *(p<0.05) significantly different from control cells in HT-1376 cell line twenty-four 
hours after irradiation-PorGal8. 
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In control HT-1376 cells vimentin labelling revealed a filamentous network in the 
cytoplasm, which extends towards the cell edge. Thirty minutes after irradiation, the vimentin 
also appeared as a filamentous network in the cytoplasm, that was near to the plasma membrane 
but rarely extended to it. Twenty-four hours after irradiation, most of the cells staining is reduced 
(Fig. 12)  
 
Figure 12. Changes of vimentin in HT-1376 cells 30 min and 24 h after targeted PDT with PorGal8. 
Immunofluorescence detection of vimentin (red). The nuclei were stained with DAPI (blue). Scale 
bars 20 m. 
 
Staining with Phalloidin-TRITC (for detection of F-actin) in both UM-UC-3 and HT-1376 
control cells showed the presence of long stress fibres (Fig. 13 and 14). Thirty minutes after 
irradiation, UM-UC-3 cells were rounded and showed a retraction of actin filaments with loss of 
stress fibres. Twenty-four hours after treatment, some features of actin disorganization remained 
present, no stress fibres were observed and phalloidin fluorescence was stronger in locations of 
cell-to-cell contact (Fig. 13). 
After thirty minutes, similar to what observed to UM-UC-3 cells, HT-1376 cells showed a 
clear retraction of actin filaments with loss of stress fibers. However, twenty-four hours after 
treatment, some cells present some reorganization in actin filaments, presenting short stress 
fibers, long extensions, like large filopodia, which suggests a possible recovery (Fig. 14).  
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Figure 13. Changes of F-actin in UM-UC-3 cells 30 min and 24 h after targeted PDT with PorGal8. 
Phalloidin-TRITC visualization of F-actin (red). The nuclei were stained with DAPI (blue). Scale bars 
20 m. 
 
  
Figure 14. Changes of F-actin in HT-1376 cells 30 min and 24 h after targeted PDT with PorGal8. 
Phalloidin-TRITC visualization of F-actin (red). The nuclei were stained with DAPI (blue). Scale bars 
20 m. 
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RhoA is a protein belonging to RhoA GTPases family involved with a multitude of cellular 
processes including, but not limited to, cell division, actin cytoskeleton regulation and induction of 
formation of stress fibers and focal adhesion points. In order to evaluate whether cytoskeleton 
changes and cell death are correlated with changes in RhoA protein levels, Western blot analysis 
was performed. Preliminary data showed that RhoA protein levels were not altered in UM-UC-3 
cells 30 min or 24 h after PorGal8-PDT (Fig. 15A). Interestingly, RhoA protein levels showed a 
tendency towards an increase in HT-1376 cells twenty-four hours after PorGal8-irradiation (Fig. 
15B).  
 
 
Figure 15. Western Blotting analysis and quantification of RhoA expression in UM-UC-3 (panel 
A) and HT-1376 (panel B) cell lines thirty minutes and twenty-four hours after irradiation. β-
actin was blotted as loading control. Quantitative analysis of RhoA (normalized to β-actin) 
expressed as ratio to levels found in control cells (cells incubated with PBS instead of PorGal8) in 
UM-UC-3 and HT-1376 cell lines. Data represents the mean ± S.E.M. of at least three independent 
experiments in UM-UC-3 cell line. Preliminary results from UM-UC-3 cell line do not present 
significant alteration in RhoA levels. HT-1376 cell line shows increase in the expression of RhoA 
twenty-four hours after irradiation-PorGal8.  
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Chapter 5. Discussion  
Many photosensitizers exist in the market and although their potential as anti-cancer 
drugs used in PDT is well established, the exact mechanisms underlying their phototoxic effects 
are relatively unknown. The major mechanisms described in PDT that activate cell death indicate 
that a diverse set of different pathways can be activated, being dependent, among other factors, 
on the cell line, light fluence rate and photosensitizer (Castano et al. 2005; Ball et al. 2001).  
Current available PS lack enough tumor selectivity, which can cause side effects in the 
healthy surrounding tissues. Many efforts have been made to develop novel PS with tumor 
selectivity, by conjugation with biomolecules, such as carbohydrates (Zheng et al. 2011; 
Vedachalam et al. 2011; Lourenco et al. 2014).  
A galactodendritic porphyrin (PorGal8) had been engineered (at QOPNA, Department of 
Chemistry, University of Aveiro) to possess four dendritic units of galactose attached as dimeric 
units to a porphyrin which confers benefits in PDT. In fact, PorGal8 had shown improved water 
solubility, high photo stability, the ability to induce the production of oxygen singlet, and 
improved selectivity to tumor cells, by interaction with galectin-1 that is overexpressed in bladder 
cancer (Pereira et al. 2016; Cindolo et al. 1999).  
More recently, we have validated PorGal8 as a novel therapeutic agent for the treatment 
of tumours exhibiting high levels of galectin-1. We have shown a specific uptake of this PS and 
induction of ROS-mediated cell death (Pereira et al. 2016). 
This study was designed to evaluate whether changes in cytoskeletal components are 
correlated with cell death triggered by PDT with PorGal8. Uptake studies showed a concentration-
dependent intake of PorGal8 in the cell lines, with maximum reached at 10-12.5 µM. At 10 µM, 
UM-UC-3 cell line possessed a higher uptake, of at least 5-fold compared to HT-1376 cell line. The 
higher PorGal8 uptake in UM-UC-3 cells can be explained by the high expression of galectin-1 
(Pereira et al. 2016; Camby et al. 2002). In fact, in vitro studies from our laboratory have shown 
preferential accumulation of PorGal8 in cancer cells overexpressing galectin-1, accompanied by 
high phototoxicity. Also, by knockdown galectin-1 protein in bladder cancer cells, we have also 
found a significant decrease of PS uptake and phototoxicity, suggesting the role of galectin-1 in 
PorGal8 selectivity (Pereira et al. 2016). 
As expected, we found that PorGal8 did not induce cell death in the dark. However, 
twenty-four hours after photodynamic activation, PorGal8 induced a significant decrease in cell 
viability in both cell lines, assessed by MTT colorimetric and Trypan Blue assays. PorGal8 led to a 
higher cytotoxicity after PDT in UM-UC-3 cells (approximately 50%) than in HT-1376 cells 
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(approximately 20%). Our previous studies have shown that although a strong phototoxic effect 
was observed at 72 h after treatment in UM-UC-3 cells, a certain percentage of HT-1376 cells are 
able to recover from the photodynamic effect between 24 and 72 h after PorGal8 photoactivation 
(Pereira et al. 2016).  
 It is known that cell adhesion to the substratum is mediated by integrins and other 
cellular adhesion molecules that connect the extracellular matrix to the intracellular actin 
cytoskeleton. Moreover, it has been thoroughly studied the effect of PDT in the actin filaments.  
Although adhesion proteins and actin filaments have been subject of various studies, the 
changes induced after PDT are highly variable with different effects reported. Due to this, the 
cytoskeleton changes induced after PDT are considered to be dependent on cell line, fluence rate 
and photosensitizer (Ball et al. 2001). 
 Microtubules have already been reported to play a key role in cell movement. Moreover, 
α-tubulin changes are involved in the motility of intracellular structures, such as the endoplasmic 
reticulum and actin filaments (Lee et al. 1995). A tendency towards a decrease in α-tubulin 
protein levels thirty minutes after irradiation was observed in both tested cell lines. HT-1376 cells 
presented a network rearrangement to a round shape. In our study, we found that changes in α-
tubulin levels only became significant twenty-four hours after irradiation in HT-1376 cell line 
where a significant protein level decrease is observed. Microtubules present reorganization with 
high reduction of staining and recovery of cellular shape similar to control. These reorganization 
of α-tubulin indicates an effort of HT-1376 cells in recovering from PDT. 
Intermediate filaments are one of the least studied structures in PDT mediated 
alterations, although their main component, vimentin, has been reported to increase in PDT-
treated cells. Our results did not show any significant alterations in the levels of vimentin thirty 
minutes after irradiation. However, a significant decrease in vimentin protein levels was found 
twenty-four hours after irradiation was observed in both cell lines. Although not statistically 
significant, the tendency towards an increase in vimentin protein levels thirty minutes after 
irradiation in HT-1376 cells could be taken as an indicator of cells trying to counteract the 
treatment. HT-1376 presented a small increase in protein levels, with retraction of vimentin 
network from the cell edge thirty minutes after treatment. UM-UC-3 presented a small decrease 
in protein levels. Twenty-four hours after, the statistical significance of the decrease in the protein 
levels was more accentuated in UM-UC-3 cell line. HT-1376 cells staining was highly decreased or 
nearly absent, with very few cells still presenting vimentin staining. We can hypothesize that the 
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difference obtained for vimentin protein in these two bladder cancer cell lines could be related to 
different resistance exhibited by the two cell lines to the phototoxic effect. 
Actin filaments, the most widely studied structures in PDT induced cytoskeleton 
alterations, presented similar disorganization thirty minutes after irradiation with complete loss 
of actin stress fibres in both cell lines. Twenty-four hours after irradiation however, HT-1376 cell 
line presented signs of recovery with reorganization of actin filaments and formation of new 
stress fibres. Furthermore, long extensions, like large filopodia, were observed. These 
observations allow us to speculate that the higher sensitivity of UM-UC-3 cells are due to a 
deeper, irreversible effect. In HT-1376 cells however, resistance to therapy can be associated with 
a recovery in actin filaments. 
Considering the various changes assessed in the cytoskeleton structures, it can be 
hypothesized that F-actin is not the only responsible for PDT efficiency and morphology changes, 
but a complex series of events that involve other cytoskeleton structures such as intermediate 
filaments and microtubules play a role in PDT effectiveness or resistance. Seemingly negligible 
alterations of tubulin and vimentin levels combined with subcellular redistribution after 
irradiation can afterwards dictate different treatment outcomes. Further studies, evaluating 
changes after the evaluated period, adhesion proteins variations or the effect of multiple PDT 
sessions should be evaluated in order to further understand the cellular behaviour and whether 
the effectiveness of the treatment can be increased. 
It is known that galectin-1 is involved in cell motility and cytoskeleton organization via the 
Gal-1-induced expression of RhoA (Camby et al. 2002). As previous work from our laboratory 
reported high levels of galectin-1 in UM-UC-3 cells, it was of interest to evaluate whether RhoA 
protein levels changes after PDT with PorGal8. Preliminary results showed no changes in the levels 
of RhoA in UM-UC-3 cells. Interestingly, preliminary data showed a tendency towards an increase 
of RhoA in HT-1376 cell line twenty-four hours after photoactivation of PorGal8. Further studies 
evaluating whether RhoA cellular redistribution are warranted in order to further elucidate the 
role of RhoA in PDT efficiency.  
Our results indicate that a complex web of events occurs in cytoskeletal elements that can 
justify different outcomes of the treatment. This study shows that not only actin filaments are 
affected by PDT, but also intermediate filaments and microtubules present significant changes in 
response to photodynamic treatment. Further studies are necessary to understand how these 
mechanisms are triggered and their relation to other key proteins such as adhesion proteins and 
other GTPases family proteins. 
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In summary, the results presented in this dissertation provide a better understanding of the 
relationship between the phototoxic effects of PorGal8 and the disorganization of the 
cytoskeleton structure. Rearrangements of the actin, vimentin and -tubulin cytoskeleton and 
changes in RhoA protein levels observed in this work may play an important role regulating cell 
death triggered by PDT with PorGal8. Clarifying the mechanisms underlying PDT efficiency might 
contribute to envisage new potential therapeutic adjuvants for PDT, acting on the cytoskeleton, to 
treat resistant cancers. 
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Chapter 6. Conclusions 
UM-UC-3 cell line proved to be have higher uptake and increase sensitivity to PDT with 
PorGal8.  
Cytoskeleton alterations accessed that distinct alterations in protein levels and protein 
relocation after PDT variate, with a seemingly recovery in HT-1376 cell line. Microtubules suffer 
reorganization but changes in protein levels are only observed in HT-1376 twenty-four hours post-
irradiation. Intermediate filaments although suffering similar reduction in protein levels twenty-
four hours after irradiation, alterations immediately after PDT indicate a first response that can 
dictate cellular resistance to PDT afterwards. In actin filaments, although a similar preliminary 
response in disorganization and loss of stress fibers, HT-1376 presents signs of recovery with short 
stress fibers and long extensions, like large filopodia. 
Preliminary results show an increase in RhoA levels in HT-1376 twenty-four hours after 
treatment, indicating a more complex web of events unfolding that the one previously presumed.  
We proved that cytoskeleton alterations cover a wider series of structures that the ones 
usually described, with indication that statistically negligible alterations immediately after 
irradiation may play a role in later survival. Briefly, we believe this is the first work that tries to 
connect a wider series of cytoskeleton alterations with PDT efficiency and cell death. 
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